Rene V. D. G.
- Country
- The Netherlands
- Department
- N/A
Research Overview
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Phase 3 Randomized Study of Epcoritamab Plus R-CHOP Versus R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients
Data & Insights
Has run more than one trial at 30 of 236 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL), focusing on innovative therapeutic approaches for newly diagnosed patients.
- B-Cell Lymphomas
- Combination Therapy Strategies
- First-line Treatment Protocols
Their research interests encompass the evaluation of novel therapeutic combinations in lymphoma treatment.
Immunotherapy Research
The investigator explores targeted immunotherapy approaches in lymphoma treatment, particularly focusing on antibody-based therapies.
- Bispecific Antibodies
- Immunotherapy Combinations
- Novel Treatment Regimens
Their work involves integrating new immunotherapeutic agents with established treatment protocols.
Treatment Outcomes
The investigator studies progression-free survival in aggressive lymphomas, particularly focusing on high-risk patient populations.
- Clinical Efficacy Assessment
- Safety Evaluation
- Risk-Based Treatment Approaches
Their research emphasizes improving outcomes for patients with advanced disease profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.